Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral ...( Top-line data exp...),Health

Top-line data expected in early 2008

TARRYTOWN, N.Y., Dec. 3 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has completed patient enrollment in the Phase IIb "Neuracept" trial for EpiCept(TM) NP-1 cream. EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

This Phase IIb trial compares the active ingredients in NP-1 against placebo in patients suffering from diabetic peripheral neuropathy (DPN), the most common form of neuropathic pain. Only two medications are currently available in the United States for the treatment of DPN. The four-week, 200- patient trial is intended to confirm and expand upon earlier work that provided a preliminary efficacy signal in this type of neuropathic pain. The primary endpoint for the Phase IIb trial is the difference between active and placebo changes in pain intensity from baseline compared to the average over the last seven days of treatment.

"We are pleased to have reached another key clinical milestone that we established for 2007, and to have advanced another one of our product candidates," stated Jack Talley, President and Chief Executive Officer of EpiCept. "We believe NP-1 holds the largest market potential of the pain candidates in our portfolio. Treatment of neuropathic pain is a billion dollar opportunity. We believe that NP-1 has the potential to become a new and efficacious topical treatment without the inherent systemic side effects of alternative treatments for the 15 million Americans who suffer from peripheral neuropathies. We expect to report top-line results from this trial in early 2008."

In addition to t
'/>"/>